JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

Search

Smith & Nephew PLC ADR

Открыт

33.95 -0.59

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

33.73

Макс.

34.23

Ключевые показатели

By Trading Economics

Доход

296M

Продажи

3B

P/E

Средняя по отрасли

30.423

90.422

Дивидендная доходность

2.26

Рентабельность продаж

9.895

Сотрудники

17,000

EBITDA

723M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+0.94% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.26%

2.13%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

15B

Предыдущая цена открытия

34.54

Предыдущая цена закрытия

33.95

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Smith & Nephew PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 февр. 2026 г., 23:52 UTC

Приобретения, слияния, поглощения

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 февр. 2026 г., 23:52 UTC

Приобретения, слияния, поглощения

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 февр. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 февр. 2026 г., 23:38 UTC

Обсуждения рынка

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 февр. 2026 г., 23:28 UTC

Обсуждения рынка

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 февр. 2026 г., 23:23 UTC

Отчет

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 февр. 2026 г., 22:57 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 февр. 2026 г., 22:08 UTC

Обсуждения рынка

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 февр. 2026 г., 21:51 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

2 февр. 2026 г., 21:49 UTC

Отчет

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 февр. 2026 г., 21:39 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 21:36 UTC

Отчет

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 февр. 2026 г., 21:34 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 21:28 UTC

Приобретения, слияния, поглощения

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 февр. 2026 г., 21:23 UTC

Отчет

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 февр. 2026 г., 21:19 UTC

Отчет

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 февр. 2026 г., 21:17 UTC

Отчет

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 февр. 2026 г., 21:17 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 21:10 UTC

Отчет

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 февр. 2026 г., 21:08 UTC

Отчет

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 февр. 2026 г., 21:07 UTC

Отчет

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies 4Q Net $608.7M >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies 4Q Rev $1.41B >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 февр. 2026 г., 21:05 UTC

Отчет

Palantir Technologies 4Q EPS 24c >PLTR

2 февр. 2026 г., 20:40 UTC

Обсуждения рынка

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение c конкурентами

Изменение цены

Smith & Nephew PLC ADR Прогноз

Целевая цена

By TipRanks

0.94% рост

Прогноз на 12 месяцев

Средняя 34.46 USD  0.94%

Максимум 34.91 USD

Минимум 34 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

0

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

26.64 / 28.37Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat